* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:17:26 ON 10 JUL 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:17:41 ON 10 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2003 HIGHEST RN 545225-95-4
DICTIONARY FILE UPDATES: 9 JUL 2003 HIGHEST RN 545225-95-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 927324.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:18:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    969 TO ITERATE

100.0% PROCESSED     969 ITERATIONS                          16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        17513 TO    21247
PROJECTED ANSWERS:              80 TO      560

L2            16 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   1.60       1.81

FILE 'CAPLUS' ENTERED AT 18:20:20 ON 10 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 10 Jul 2003  VOL 139 ISS 2
FILE LAST UPDATED: 9 Jul 2003  (20030709/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l2
L3            4 L2

=> d l3 1-4 ibib abs hitstr

L3   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2002:184900  CAPLUS
DOCUMENT NUMBER:          136:247577
TITLE:                    Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-
                          c]pyridines as cathepsin S inhibitors for treating
                          allergies
INVENTOR(S):              Cai, Hui; Edwards, James P.; Gu, Yin; Karlsson, Lars;
                          Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan;
                          Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S):       Ortho McNeil Pharmaceutical, Inc., USA
SOURCE:                   PCT Int. Appl., 115 pp.
                          CODEN: PIXXD2
```

09/288,556

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020013	A2	20020314	WO 2001-US27480	20010905
WO 2002020013	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002040019	A1	20020404	US 2001-927188	20010810
AU 2001088731	A5	20020322	AU 2001-88731	20010905
EP 1315492	A2	20030604	EP 2001-968487	20010905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-230407P P 20000906
US 2001-927188 A 20010810
US 2000-225178P P 20000814
WO 2001-US27480 W 20010905

OTHER SOURCE(S): MARPAT 136:247577
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; Q = O, S, or (un)substituted N; S, T, Y, and Z = independently N or (un)substituted C;

R5 and R6 = independently H or alkyl; R7 and R8 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R7R8 = (un)substituted carbocyclic or heterocyclic ring; R32 = H, (hydroxy)alkyl, CN, acyl, carbamoyl, CHO, or alkoxycarbonyl; n = 0-2; or pharmaceutically acceptable salts, amides, esters, or stereoisomers thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, 1-methanesulfonylpiperidin-4-one (prepn. given) was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-CF3C6H4COCl, followed by cycloaddn. with H2NNH2, gave 5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazol[4,3-c]pyridine (72%). Alkylation with epichlorohydrin (35%) and addn. of 5-chloro-3-piperidin-4-yl-1H-indole (prepn. given) afforded II (88%). The latter inhibited recombinant human cathepsin S with IC50 of 0.07 .mu.M.

IT **400801-53-8P**, 3-(1-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl]-piperidin-4-yl)-1H-indole-5-carboxylic acid ethyl ester
400801-58-3P, 1-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-[4-(5-oxy-1H-pyrrolo[3,2-c]pyridin-3-yl)-piperidin-1-yl]-propan-2-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of phenylpyrazolopyridine antiallergy agents from piperidinones, benzoyl chlorides, and hydrazine)

RN 400801-53-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[1-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 400801-58-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-.alpha.-[[4-(5-oxido-1H-pyrrolo[3,2-c]pyridin-3-yl)-1-piperidinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:184898 CAPLUS
DOCUMENT NUMBER: 136:247575
TITLE: Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
INVENTOR(S): Butler, Christopher R.; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gu, Yin; Gustin, Darin J.; Karlsson, Lars; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sehon, Clark A.; Sun, Siquan; Tays, Kevin L.; Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

applicants

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020011	A2	20020314	WO 2001-US27429	20010905
WO 2002020011	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003078419	A1	20030424	US 2001-927324	20010810
AU 2001088706	A5	20020322	AU 2001-88706	20010905
EP 1315490	A2	20030604	EP 2001-968461	20010905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-230407P P 20000906
US 2001-927324 A 20010810
US 2000-225178P P 20000814
WO 2001-US27429 W 20010905

OTHER SOURCE(S): MARPAT 136:247575
GI



I



II

AB Title compds. I [wherein Ar and Ar2 = independently (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; W = O, S, (un)substituted N or CH, CO, CONH, NHCO, or a bond; R5 and R6 = independently H or alkyl; R7 and R8 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, or (un)substituted carbocyclyl or heterocyclyl; or R7R8 form an (un)substituted carbocyclic or heterocyclic ring; Rz = H, OH, or is absent; n = 0-2; or pharmaceutically acceptable salts, amides, esters, or stereoisomers thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, N-acetyl-4-piperidone was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-ClC6H4COCl and cycloaddn. of the product with H2NNH2 gave 1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone (42%). Alkylation with epichlorohydrin (60%), followed by addn. of 1,4-dioxa-8-azaspiro[4.5]decane (81%), conversion to the piperidinone (65%), and reductive addn. of 2-aminobenzonitrile (20%), afforded II. The latter inhibited recombinant human cathepsin S with IC50 of 0.73 .mu.M.

IT **400797-30-0P**, 1-[1-[3-[4-(Benzothiazol-2-ylamino)piperidin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400797-65-1P**, 1-[1-[3-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydro-1H-quinazolin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiallergy agent; prepn. of phenylpyrazolopyridines as cathepsin S inhibitors for treating allergies)

RN 400797-30-0 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-benzothiazolylamino)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



546-119

RN 400797-65-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)-1-piperidinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



544-284

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:142709 CAPLUS
DOCUMENT NUMBER: 136:200183
TITLE: Substituted and/or fused pyrazoles, particularly indolylpiperidinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Cai, Hui; Edwards, James P.; Meduna, Steven P.; Pio, Barbara A.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

applicants

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014317	A2	20020221	WO 2001-US25180	20010810
WO 2002014317	A3	20020704		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001084823	A5	20020225	AU 2001-84823	20010810
US 2002040019	A1	20020404	US 2001-927188	20010810
EP 1309592	A2	20030514	EP 2001-963912	20010810

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 2000-225178P	P	20000814
	US 2001-927188	A	20010810
	WO 2001-US25180	W	20010810

OTHER SOURCE(S): MARPAT 136:200183

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [W, X, Y, Z = N, (un)substituted CH (0-3 of them may be N; or 1 can be N-oxide when other 3 .noteq. N); R = H, alkyl, cyano, hydroxyalkyl, acyl, CHO, alkoxycarbonyl, or (un)substituted carbamoyl; R1, R2 = H, alkyl; R3, R4 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R3R4 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; Ar = (un)substituted mono- or bicyclic (hetero)aryl; n = 0-2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); Q = O, S, (un)substituted NH; including stereoisomers, pharmaceutically acceptable salts, esters, and amides]. Claimed uses include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 70 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 13 compds. For instance, 6-(morpholin-4-yl)-3-(piperidin-4-yl)-1H-pyrrolo[3,2-c]pyridine (prepd. in 5 steps) reacted with the corresponding epoxide (prepd. in several steps) to give title compd. II, a preferred compd. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.02 .mu.M. Compd. III is another one of four specifically preferred compds.

IT **400801-53-8P**, 3-[1-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-1H-indole-5-carboxylic acid ethyl ester
400801-58-3P, 1-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-3-[4-(5-oxy-1H-pyrrolo[3,2-c]pyridin-3-yl)piperidin-1-yl]propan-2-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of indolylpiperidinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400801-53-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[1-[2-hydroxy-3-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 400801-58-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 4,5,6,7-tetrahydro-5-(methylsulfonyl)-.alpha.-[[4-(5-oxido-1H-pyrrolo[3,2-c]pyridin-3-yl)-1-piperidinyl]methyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:142708 CAPLUS
DOCUMENT NUMBER: 136:200182
TITLE: Substituted and/or fused pyrazoles, particularly piperidinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Butler, Christopher R.; Cai, Hui; Edwards, James P.; Grice, Cheryl A.; Gustin, Darin J.; Khatuya, Haripada; Meduna, Steven P.; Pio, Barbara A.; Sehon, Clark A.; Tays, Kevin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014315	A2	20020221	WO 2001-US25290	20010810
WO 2002014315	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001086454	A5	20020225	AU 2001-86454 20010810
US 2003078419	A1	20030424	US 2001-927324 20010810
EP 1309593	A2	20030514	EP 2001-965898 20010810

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-225178P P 20000814
US 2001-927324 A 20010810
WO 2001-US25290 W 20010810

OTHER SOURCE(S): MARPAT 136:200182
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [R = H, OH, or absent; R1, R2 = H, alkyl; R3, R4 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R3R4 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; Ar1 = (un)substituted mono- or bicyclic (hetero)aryl; Ar2 = (un)substituted (un)satd. (non)arom. mono- or bicyclic ring system with 0-5 heteroat. ring moieties selected from O, S, N, SO2, and CO; n = 0-2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); W = O, S, CO CONH, NHCO, (un)substituted NH or CH2; including stereoisomers, pharmaceutically acceptable salts, esters, and amides]. Claimed usages include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 350 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 31 compds. For instance, 6-chloro-1-(piperidin-4-yl)-3,4-dihydro-1H-quinolin-2-one (prepd. in 6 steps) reacted with the corresponding epoxide (prepd. in several steps) to give title compd. II. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.01 .mu.M. Compd. III is one of two specifically preferred compds.

IT **400797-30-0P**, 1-[1-[3-[4-(Benzothiazol-2-ylamino)piperidin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400797-65-1P**, 1-[1-[3-[5-Methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]-3,4-dihydro-1H-quinazolin-2-one **400798-30-3P**, 1-[1-[3-[5-Acetyl-3-(4-bromophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-6-chloro-3,4-dihydro-1H-quinolin-2-one **400798-35-8P**, 1-[1-[3-[4-(6-Chloro-2,2-dioxo-2,3-dihydro-2.lambda.6-2,1,3-benzothiadiazol-1-yl)piperidin-1-yl]-2-hydroxypropyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400798-44-9P**, 4-[1-[3-[3-(4-Bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-6-chloro-4H-1,4-benzoxazin-3-one **400798-59-6P**, 1-[1-[3-[5-Acetyl-3-(4-nitrophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-1,3-dihydroindol-2-one **400798-73-4P**, 1-[3-(4-Chloro-3-methylphenyl)-1-[2-hydroxy-3-[4-(2-methyl-2,3-dihydroindol-1-yl)piperidin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone

400799-11-3P, N-[1-[3-[5-Acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-N-(3-chlorophenyl)acetamide **400799-21-5P**, 1-[3-(4-Chlorophenyl)-1-[2-hydroxy-3-[4-(3-methoxyphenylamino)piperidin-1-yl]propyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone **400799-26-0P**, [2-[[1-[3-[3-(4-Bromophenyl)-5-(methanesulfonyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]amino]-4-(ethanesulfonyl)phenoxy]acetic acid methyl ester **400799-42-0P**, 2-[1-[3-[3-(4-Bromophenyl)-5-methanesulfonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yloxy]benzonitrile **400799-49-7P**, 1-[1-[3-[5-Acetyl-3-(4-iodophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-1,3-dihydrobenzimidazol-2-one **400799-57-7P**, 1-[1-[3-[5-Acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]piperidin-4-yl]-3-ethyl-1,3-dihydrobenzimidazol-2-one **400799-65-7P**, 1-[2-Hydroxy-3-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]propyl]-3-(4-trifluoromethylphenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylic acid amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperidinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400797-30-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2-benzothiazolylamino)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400797-65-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine, 1-[3-[4-(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)-1-piperidinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400798-30-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-bromophenyl)-.alpha.-[[4-(6-chloro-3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400798-35-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(6-chloro-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 400798-44-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-(6-chloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



541-105

RN 400798-59-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2,3-dihydro-2-oxo-1H-indol-1-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 400798-73-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(2,3-dihydro-2-methyl-1H-indol-1-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400799-11-3 CAPLUS
CN Acetamide, N-[1-[3-[5-acetyl-3-(4-chloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl]-4-piperidinyl]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 400799-21-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chlorophenyl)-4,5,6,7-

tetrahydro-.alpha.-[[4-[(3-methoxyphenyl)amino]-1-piperidinyl]methyl]-
(9CI) (CA INDEX NAME)



RN 400799-26-0 CAPLUS
CN Acetic acid, [2-[[1-[3-[3-(4-bromophenyl)-4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl]-4-piperidinyl]amino]-4-(ethylsulfonyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 400799-42-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 3-(4-bromophenyl)-.alpha.-[[4-(2-cyanophenoxy)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



RN 400799-49-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-.alpha.-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro-3-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 400799-57-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol, 5-acetyl-3-(4-chloro-3-methylphenyl)-.alpha.-[[4-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 400799-65-7 CAPLUS
CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1-[3-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-hydroxypropyl]-1,4,6,7-tetrahydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)